论文部分内容阅读
目的:评价重组人纤维连接蛋白(Retro Nectin,RN)诱导的CIK细胞治疗晚期癌症患者的安全性及疗效。方法:观察85例晚期癌症患者,经RN诱导的自体或异体血CIK细胞治疗的安全性。选择晚期非小细胞肺癌患者36例,分为2组:CIK细胞治疗组20例,化疗组16例,比较两组治疗前后的免疫功能、生活质量(用汉化生活量表QLICP系统测试)、临床疗效差异;选择晚期非小细胞肺癌患者32倒,分为CIK细胞治疗组及姑息治疗组各16例,比较两组患者的生存期。结果:安全性:自体及异体CIK细胞治疗过程中主要出现兴奋感、失眠、低热,未见明显毒副反应。近期疗效:20例患者经CIK细胞治疗:PR 1例,SD 10例,PD 9例,ORR 5.00%,DCR 55.00%;16例患者经化疗:PR 5例,SD 5例,PD 6例,ORR 31.25%,DCR 62.50%,2组的DCR差异不显著(P>0.05),但化疗组的ORR明显高于CIK组(P<0.05)。在生活质量方面,化疗后病人心理模块中情绪方面明显低落(P<0.05),CIK细胞治疗的患者多有生活质量提高;CIK细胞治疗组与化疗组患者,治疗前后免疫功能无显著差异(P>0.05)。CIK细胞治疗组(11.0个月)比姑息治疗组(6.0个月)中位生存期延长,但总生存时间无统计差异(x~2=2.301,P=0.129)。结论:RN诱导的CIK细胞自体及异体治疗均简便、安全、有效,可以改善晚期肿瘤病人的生活质量,延长生存期。
Objective: To evaluate the safety and efficacy of CIK cells induced by recombinant human connexin (RN) in the treatment of patients with advanced cancer. Methods: The safety of CIK-induced autologous or allogeneic CIK cells in 85 patients with advanced cancer was observed. Thirty-six patients with advanced non-small cell lung cancer (NSCLC) were divided into two groups: 20 in CIK cell group and 16 in chemotherapy group. The immune function, quality of life (QLICP system test with Chinese Life Scale) There were 32 patients with advanced non-small cell lung cancer who were divided into CIK cell therapy group and palliative treatment group, with 16 cases in each group. The survival of the two groups was compared. Results: Safety: The excitability, insomnia and hypothermia mainly appeared in the course of the treatment of autologous and allogeneic CIK cells with no obvious side effects. Short-term efficacy: CIK cells were treated in 20 patients: PR 1, SD 10, PD 9, ORR 5.00%, and DCR 55.00%. Sixteen patients underwent chemotherapy: PR 5, SD 5, PD 6 31.25%, and DCR 62.50%. There was no significant difference in DCR between the two groups (P> 0.05). However, the ORR in the chemotherapy group was significantly higher than that in the CIK group (P <0.05). In terms of quality of life, there was a significant decrease in emotion in the psychological module of patients after chemotherapy (P <0.05), and patients with CIK cells had more quality of life. There was no significant difference in immune function between CIK cell therapy group and chemotherapy group before and after treatment (P > 0.05). The median survival was longer in the CIK cell-treated group (11.0 months) than in the palliative treatment group (6.0 months), but there was no statistical difference in overall survival (x 2 = 2.301, P = 0.129). CONCLUSIONS: RN-induced CIK cells are both simple, safe and effective in the treatment of CIK cells, which can improve the quality of life and prolong the survival of patients with advanced cancer.